GlassScriptPhysician profile
David S Heath
NPI 1326405846
$3,174.24
in general payments reported to CMS, 2019-2025
34 companies · $87.53 in 2025
The $87.53 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $804 · 2023: $1,272 · 2024: $1,011 · 2025: $87.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $708.28 | 2022-2025 | Mavenclad |
| Abbvie INC. | $642.38 | 2022-2024 | |
| Eisai INC. | $169.96 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $150.09 | 2022-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $144.64 | 2022 | |
| Csl Behring | $120.66 | 2023-2024 | Hizentra |
| Sk Life Science, INC. | $117.68 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $107.01 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $91.64 | 2023-2024 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $81.22 | 2024 | Nuplazid |
| Biogen, INC. | $77.95 | 2023-2024 | Tysabri, Vumerity, Plegridy |
| Amneal Pharmaceuticals LLC | $75.30 | 2023-2024 | Rytary, Lyvispah |
| Otsuka America Pharmaceutical, INC. | $72.66 | 2023-2024 | Nuedexta, Rexulti |
| Alexion Pharmaceuticals, INC. | $60.32 | 2023-2024 | Ultomiris |
| Celgene Corporation | $52.24 | 2023-2024 | Zeposia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $50.48 | 2022-2024 | Valtoco |
| Harmony Biosciences LLC | $49.34 | 2022-2023 | Wakix |
| Lilly USA, LLC | $42.61 | 2022-2024 | Amyvid |
| Axsome Therapeutics, INC. | $34.75 | 2023 | Sunosi |
| Argenx US, INC. | $34.23 | 2023-2024 | Vyvgart |
| Lundbeck LLC | $33.66 | 2023-2024 | Vyepti |
| Ucb, INC. | $24.16 | 2023 | |
| Kyowa Kirin, INC. | $23.88 | 2024 | Nourianz |
| Impel Pharmaceuticals INC. | $22.82 | 2023 | Trudhesa |
| Mirati Therapeutics, INC. | $21.72 | 2023 | Krazati |
| Tg Therapeutics, INC. | $21.34 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.17 | 2024 | Keveyis |
| Jazz Pharmaceuticals INC. | $20.05 | 2022 | |
| Pfizer INC. | $18.24 | 2024 | |
| Sandoz INC. | $17.53 | 2024 | Zarxio |
| Livanova USA, INC. | $17.17 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novo Nordisk INC | $16.91 | 2025 | Ozempic |
| Medtronic, INC. | $16.28 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.87 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.